Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Postow

Showing results (141-150 of 212) with videos related to

Pageof 22
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 20, 2021
CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of <sup>89</sup>Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 MinibodyMichael D Farwell, Raymond F Gamache, Hasan Babazada, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 17, 2018
Tumor Board Conferences for Multidisciplinary Skin Cancer Management: A Survey of US Cancer CentersShoko Mori, Cristian Navarrete-Dechent, Tatyana A Petukhova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2014
American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatmentJeffrey S Weber, Laura A Levit, Peter C Adamson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2017
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III TrialsDirk Schadendorf, Jedd D Wolchok, F Stephen Hodi, et al.
Ophthalmology|July 16, 2017
Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous ChorioretinopathyJasmine H Francis, Larissa A Habib, David H Abramson, et al.
Nature Medicine|May 1, 2019
Rational design of anti-GITR-based combination immunotherapyRoberta Zappasodi, Cynthia Sirard, Yanyun Li, et al.
Science Translational Medicine|July 20, 2018
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanomaScott J Rodig, Daniel Gusenleitner, Donald G Jackson, et al.
Biorxiv : the Preprint Server for Biology|September 4, 2024
Spatial Immunophenotyping from Whole-Slide Multiplexed Tissue Imaging Using Convolutional Neural NetworksMohammad Yosofvand, Sharon N Edmiston, James W Smithy, et al.
Journal for Immunotherapy of Cancer|June 22, 2023
Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitisYousef R Badran, Fangwen Zou, Sienna M Durbin, et al.
Journal of Translational Medicine|November 5, 2017
The need for a network to establish and validate predictive biomarkers in cancer immunotherapyGiuseppe V Masucci, Alessandra Cesano, Alexander Eggermont, et al.
Pageof 22

Showing results (141-150 of 212) with videos related to

Sort By:
Pageof 22
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 20, 2021
CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of <sup>89</sup>Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 MinibodyMichael D Farwell, Raymond F Gamache, Hasan Babazada, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 17, 2018
Tumor Board Conferences for Multidisciplinary Skin Cancer Management: A Survey of US Cancer CentersShoko Mori, Cristian Navarrete-Dechent, Tatyana A Petukhova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2014
American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatmentJeffrey S Weber, Laura A Levit, Peter C Adamson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2017
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III TrialsDirk Schadendorf, Jedd D Wolchok, F Stephen Hodi, et al.
Ophthalmology|July 16, 2017
Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous ChorioretinopathyJasmine H Francis, Larissa A Habib, David H Abramson, et al.
Nature Medicine|May 1, 2019
Rational design of anti-GITR-based combination immunotherapyRoberta Zappasodi, Cynthia Sirard, Yanyun Li, et al.
Science Translational Medicine|July 20, 2018
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanomaScott J Rodig, Daniel Gusenleitner, Donald G Jackson, et al.
Biorxiv : the Preprint Server for Biology|September 4, 2024
Spatial Immunophenotyping from Whole-Slide Multiplexed Tissue Imaging Using Convolutional Neural NetworksMohammad Yosofvand, Sharon N Edmiston, James W Smithy, et al.
Journal for Immunotherapy of Cancer|June 22, 2023
Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitisYousef R Badran, Fangwen Zou, Sienna M Durbin, et al.
Journal of Translational Medicine|November 5, 2017
The need for a network to establish and validate predictive biomarkers in cancer immunotherapyGiuseppe V Masucci, Alessandra Cesano, Alexander Eggermont, et al.
Pageof 22